glp-1 7-36 CAS 107444-51-9 Glucagon-like peptide 1 (GLP1, 7-36)

Another 2024 study found that people with breast cancer and type 2 diabetes taking GLP-1 drugs had fewer major cardiovascular problems (conditions related to heart and blood vessels) after receiving cardiotoxic breast cancer treatments such as anthracyclines and HER2 inhibitors, compared to people not taking GLP-1 drugs

& Schwartz, M

PlexusDx reviews your complete health history to determine whether semaglutide aligns with your clinical needs, regardless of whether your BMI strictly meets the 30 threshold

Audrey's story references pre-diabetes and PCOS alongside her experience

While there's no direct proof that these GLP-1 drugs are driving the drops we're now seeing in obesity rates, given their increasing use and how effective we know they are, it seems likely